Un gran honor y una gran responsabilidad. Gracias @secardiologia por poner el foco en la humanizacion de la Medicina.

⚠️ Heart failure pharmacotherapy for patients with HFrEF and concomitant atrial fibrillation‼️ 📍A @escardio consensus statement‼️ @secardiologia @SACardiologia @ICardiacaSEC @clinica_sec @MartaCoboMarcos @rdelaespriella @alejandroipc2 https://t.co/kiHxppZI41

Enhorabuena a @yulnunezvill por este merecido reconocimiento de The American College of Cardiology and the editorial board of JACC: Heart Failure: “the Most Published Author Award” Es un honor tenerte en nuestra candidatura @JuntosSEC25 . Eres garantía segura de que tu

What's new in heart failure? September 2025 https://t.co/LVYGPpssmb #EJHF @EJHFEiC @ESC_Journals #HeartFailure

#Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial #Cardiomyocytes This study suggests the preventive role of semaglutide, #GLP1-RA , on CV system based on genesis of inflamed epicardial fat https://t.co/337e19SUQQ

Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Read this State-of-the-Art review just published in #EHJ 👉 https://t.co/xs8gK2WEW0 @RoccoMontone @ehj_ed #amyloidosis

Inauguración de la III Jornada CARE ME #HospitalClinic y #HospitalValDHebron Sumando sinergias. #IgnacioFerreira, @masitges @MartaFarrero #EstebanPoch

Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity Glucagon-like peptide-1 receptor agonists reduce HFH and CV death across CKM conditions, with generally consistent

Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement Necesaria y obligada publicación. De obligada lectura. Ya incluido el FAI. 🔥🧈 (en mi opinión la revolución en el diagnóstico de la placa vulnerable y la predicción de MACEs ) https://t.co/3CUxDocpIT

For anyone who has wanted a clear, authoritative summary of inflammation and cardiovascular disease, and where the science is heading, here it is. The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease. @JACCJournals

🔥New Scientific Statement from #HFA & #HFAI: SGLT2 inhibitors for the prevention & treatment of #HeartFailure Key recommendations across the HF spectrum: 📍At risk for HF: ⬇️HF events in patients with #T2DM & #CKD, initiate #SGLT2i 📍Post-AMI: ⬇️HFh alone, consider in

¿Aún no has visto nuestra propuesta electoral? En 1:43 te explicamos nuestro proyecto y te queremos convencer de que nos votes #JuntosSEC25 ⁦@almucastro01⁩ ⁦@OjedaOjeda18⁩ ⁦@yulnunezvill⁩

⚠️⚠️⚠️⚠️. Ojo que el tratamiento de la obesidad no es lo mismo que el tratamiento para las complicaciones cardiovasculares y renales de la obesidad.

Actualización del posicionamiento sobre obesidad y enfermedad cardiovascular y renal de las Asociaciones de Cardiología Preventiva, Cardiología Clínica e Insuficiencia Cardiaca de la SEC #reccardioclinics @almucastro01 @Dr_Manito https://t.co/yl0z4tQEpN

🫀 Hypertrophic Cardiomyopathy (HCM) — a classic but evolving story. Thickened myocardium, outflow obstruction, and now... targeted therapy. Dr Eugene Braunwald explaining diagnosis, imaging & the promise of myosin inhibitors. 📖 https://t.co/HKppTzOC7A #HCM @NEJM

📢 New publication in ESC Heart Failure: "Epicardial, visceral and subcutaneous adipose tissue in heart failure with preserved ejection fraction". 👉 https://t.co/0lh0XATp1G #HFpEF #HeartFailure #ESCHeartFailure #HFA_ESC @EJHFEiC @JanBiegus @Ppponikowski @hvanspall

Atrial Functional Mitral Regurgitation and Exercise-Induced Changes in Heart Failure With Preserved Ejection Fraction AFMR is common in HFpEF and independently associated with adverse outcomes when moderate or severe at rest. Even mild, exercise-induced increases carry

A beautiful "explainer" of everything a cardiologist needs to know about #eGFR in HF clinical practice with modern #GDMT ...and a plug to bring back #eGFRslope as an endpoint in HF clinical trials New in #EHJ with leading nephrologists @brendonneuen https://t.co/VPkajZrztH

⚠️ Low-dose digoxin ⬆️ cardiac function in patients with HFpEF (EF > 50%) and AF: RATE-AF trial‼️ ✅ EF ⬆️ Dig > BB ✅ NT-proBNP ⬇️ Dig > BB ✅ NYHA class ⬆️ Dig > BB @secardiologia @escardio @SACardiologia @ICardiacaSEC @clinica_sec https://t.co/BostI3fQZL

Trials like #DIGITHF show us HFrEF remains one of the highest risk conditions across all of biomedicine Most pts experiencing events by 5y even when well-treated #GDMT It seems community should be open to ongoing attempts at add-on strategies even if used selectively. Thoughts?